Semua Kategori
| Product Name | Deskripsi | Action |
|---|---|---|
| Amivantamab,Rybrevant,EGFR, cMet (MET),JNJ-61186372,antibodi bispesifik EGFR/c-MET,bispesifik IgG1 manusia sepenuhnya,immunoterapi onkologi / NSCLC biologis,CAS No.2171511-58-1 | Trade Name : Rybrevant Target : EGFR, cMet (MET) Molecular Type : Bispecific Antibody Sales in 2025 (Millions of USD) : 179(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in ... |
|
| Polatuzumab vedotin,Polivy,CD79B,RG7596,ADC,Terapi yang ditargetkan CD79b,Inhibitor Mikrotubule,Oncology ADC / DLBCL ADC / Lymphoma ADC,Infusi intravena,CAS No.1313206-42-6 | Trade Name : Polivy Target : CD79B Molecular Type : ADC Sales in 2025 (Millions of USD) : 850(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Obinutuzumab ,Gazyva ,CD20 ,GA101 ,No. CAS 949142-50-1 ,Antibodi monoklonal anti-CD20 (Tipe II) ,Antibodi IgG1 yang direkayasa glikosilasi manusia ,Biologik onkologi / Biologik CLL / Biologik limfoma folikuler | Trade Name : Gazyva Target : CD20 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 784(First three quarters) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Ivonescimab,YIDAFANG® ((Nama dagang yang disetujui untuk digunakan di China),AK112,PD-1/VEGF bispecific antibody,Oncology immunotherapy / Anti-angiogenic therapy,PD-1/VEGF Bispecific antibody, CAS No.2428381-53-5 | Trade Name : YIDAFANG® (Trade names approved for use in China) Target : N/A Molecular Type : PD-1/VEGF Bispecific antibody Sales in 2025 (Millions of USD) : 28(In 2024) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this ... |
|
| Datopotamab deruxtecan-dlnk | Trade Name : Datroway Target : TROP-2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 10(First Quarter) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Tenecteplase,Metalyse,Fibrin,TNK-tPA,Thrombolytic / Fibrinolytic enzyme,tPA generasi ketiga,Recombinant Protein,CAS No.191588-94-0 | Trade Name : Metalyse Target : Fibrin Molecular Type : Recombinant Protein Sales in 2025 (Millions of USD) : 1780(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Tarlatamab ,Imdelltra ,DLL3&CD3 ,AMG 757 ,Imunoterapi onkologi / Biologis SCLC ,Infus intravena ,Sitotoksisitas yang dimediasi sel-T ,Bispesifik T-cell Engager ,No. CAS 2307488-83-9 | Trade Name : Imdelltra Target : DLL3&CD3 Molecular Type : Bispecific T-cell Engager Sales in 2025 (Millions of USD) : 215(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in ... |
|
| Serplulimab,HANSIZHUANG,PD-1,Hetronifly,HLX10,Anti-PD-1 inhibitor titik pemeriksaan kekebalan tubuh,Humanized IgG4 monoclonal antibody,Monoclonal antibody,CAS No. 2231029-82-4 | Trade Name : HANSIZHUANG Target : PD-1 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 82(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with ... |
